



- **CONTENTS**
- PRESIDENT'S MESSAGE
- SECRETARY'S MESSAGE
- EDITORIAL
- EXECUTIVE COMMITTEE MEMBERS
- CONFERENCE REPORT AROICON-BIHAR
- **ACADEMICS AND EVENTS**
- ARTICLES
- ACHIEVERS
- UPCOMING EVENTS







From the desk of President AROI- Bihar Chapter

Dear AROI-Bihar Chapter Members,

It gives me great pleasure to share that our society has now been formally registered—an important and long-awaited milestone. This achievement marks a new chapter for the AROI-Bihar Chapter, strengthening our institutional framework and enabling more structured academic and professional growth.

The past year has been both productive and inspiring. The zonal chapter meetings, excellently organized by Mahabir Cancer Sansthan and Paras Hospital under the leadership of Dr. Vinita Trivedi and Dr. Shekhar Kesari, respectively, stood out as exemplary models of academic collaboration and enthusiastic participation. Our postgraduate teaching programmes have also continued to flourish, further enriching academic standards across institutions.

The ESTRO Teaching Course, coordinated by Dr. Pritanjali Singh, added meaningful momentum to our academic calendar by bringing valuable global insights into local practice.

Another significant development has been the commencement of radiotherapy services at the Homi Jahangir Bhabha Institute, Muzaffarpur, under the leadership of Dr. Gautam Saran, Head of Radiation Oncology. This expansion will greatly enhance the availability and capacity of radiotherapy services in our region, benefiting patients across Bihar and beyond.

I also extend my heartfelt congratulations to Dr. Richa Chouhan and the editorial team for bringing out this edition of the Newsletter. We look forward to continued growth, stronger collaboration, and enriching experiences in years ahead.

I hope to meeting you all at the AROICON-2025 in Kolkata.

Warm regards,

Dr Rajiv Ranjan Prasad Director-Jay Prabha Medanta Patna



I am extremely happy and proud to have served our esteemed association in capacity of Secretary AROI General, Bihar Chapter. The 7th annual conference of AROI Bihar Chapter was held Hotel Maurya, Patna, on 12th - 13th July 2025, with the theme: "From evidence to excellence in oncology- a collective approach." I am very thankful to Dr. Shekhar Kumar Keshri & the team members for of commendable job hosting the conference good scientific with content and great hospitality under aegis of **HMRI** Paras

Hospital.

From the desk of Secretary AROI- Bihar Chapter

Our Vision and Challenges-

- Advocating at the government level to establish a Health Awareness School at the district level and block level with a team of expert doctors to impart the knowledge of health awareness.
- A regular health camp should be arranged at the village/town level, which will lead to early detection of disease, which is important in the management and treatment of cancer, and prevention by making necessary lifestyle changes.
- Recognizing cancer as a notifiable disease to ensure better tracking and job opportunities for oncologists to meet the rising burden of cancer.
- To start DM programs in Radiation Oncology.
- To make AROI members of the Bihar chapter reach greater heights with excellent knowledge and unmatched skills in oncology.
- To continue our Academic activities throughout the year with new vigor.
- Apart from all, we all should join hands in collaborative research work.

I promise to remain one amongst you and look forward to your advice and suggestions to make AROI the best Association ever. It has been a challenging and learning experience for me in this office, and I thank the office bearers, the executive committee, and all the members of AROI(BC) for supporting and standing by me.

I am pleased with a very efficient and young team to extend my best wishes to them. I am sure they will do a great Job forward.

My best wishes to all members of the Bihar chapter AROI, my colleagues, my friends, and dear students for the coming New Year 2026.

Warm regards, Dr. (Prof.) Rajesh Kumar Singh Chief State Cancer Institute, IGIMS, Patna

Editor's Note

Happy reading and a very happy new year.

Dear All

Dr Richa ChauhanEditor-in-Chief



Greetings from the Editorial team.

Welcome to the latest edition of our newsletter. As we say goodbye to the year 2025, it's time to cherish the events, achievements and academic activities of our AROI members. The newsletter is an effort to recollect the memories of the seminars and conferences held in the last academic year. It also puts forward the innovative research works and the honours achieved by our young Radiation oncologists.

A big thanks to all those who have contributed to this newsletter. Looking forward for valuable feedback and suggestions from others.

Editorial team



Dr Usha Singh



Dr Shraddha Raj



Dr Kanchan Singh

EXECUTIVE COMMITTEE MEMBERS AROI BIHAR



Dr.(Prof.)RajivRanjan Prasad **President**



Dr. Pritanjali Singh **Vice President**



Dr. Shekhar Keshri **Vice President**



Dr. Kunal Kishor **Treasurer**



Dr. Vinita Trivedi Joint Secretary



Dr. Anita Kumari Joint Secretary



Dr. Abhishek Kumar **Advisor**



Dr. Vidyanand **Prasad Advisor**



Dr.Ravi Byahut **ExecutiveMember**



Dr. (Prof.) Rajesh Kumar Singh

General Secretary



Dr. Dinesh Kumar Sinha **ExecutiveMember**



Dr. Mukesh Kumar **Bharti**

ExecutiveMember



Dr. Richa Madhawi

ExecutiveMember







Dr. Rita Rani



Dr. Sneha Jha **ExecutiveMember**



Dr. Nilesh Mani **ExecutiveMember**



Dr. RichaChauhan ChiefEditor (NewsLetter)



Dr. Usha Singh Editorlal Board (News Letter)



Dr. Shraddha Raj **Editorlal Board** (News Letter)



Dr. Kanchan Singh **Editorlal Board** (News Letter)

7th Annual Conference AROICON BIHAR CHAPTER 2025



The 7th annual conference of AROI Bihar Chapter was held successfully at Hotel Maurya, Patna on 12th and 13th July 2025, organized in association with Paras Hospital, Patna. This beautiful conference was well inaugurated by His excellency Hon' Governor of Bihar Mr. Arif Mohammed Khan. It was well attended by Delegates, Postgraduates and faculties not only from Bihar but also from different states of the country and abroad Nepal and Bangladesh.

The theme of this 7th annual conference was 'From evidence to excellence in oncology- A collaborative approach.' The Whole Scientific program was focusing on recent trends in practice of modern oncology well executed by high quality lectures delivered by renowned speakers from TMH (Mumbai), CMC (Vellore), AllMS(Delhi), RGCI (Delhi), SGPGI (Lucknow), Max (Delhi), Paras (Gurugram) and other prestigious cancer institutes of the country.

Dr. A.D. Singh oration delivered by Dr. Pankaj Chaturvedi (Director-ACTREC,TMH, Mumbai) and Dr. Rangi Prasad Singh oration delivered by Dr. Harit Chaturvedi (Director-Oncology, Max, Delhi) were held in memory of legendry in the field of Radiation oncology of the state and country.

1For the first time at the regional level, after each keynote lecture, Online quiz competition for postgraduates was held successfully. Best three abstract competition was also held among PGs, Residents and senior residents. Quality of the abstracts had been presented of high standard which were well appreciated by judges.





7th Annual Conference AROICON BIHAR

BIHAR CHAPTER 2025





The organizing secretary Dr. Shekhar Kumar Keshri (Paras HMRI,Patna) welcomed the guest speakers and all delegates to begin the conference and finally, Organizing president Dr. Rajiv Ranjan Prasad had given the vote of thankx to all respected faculty and attendees. It was a well organized collaborative conference by all executives from AROI Bihar justifying the theme a collaborative approach academically too..

THE GRACEFUL PRESENCE AND BLESSINGS OF OUR AROI NATIONAL PRESIDENT DR. S.N. SENAPATI AND SECRETARY GENERAL, NATIONAL AROI DR. V. SRINIVASAN, MADE THIS CONFERENCE A GRAND SUCCESS.





7th Annual Conference **AROICON** BIHAR CHAPTER 2025

ORATION





Oration 1: Promoting Research in India - Tata Memorial Centre Experience (Dr. A. D. Singh) by Dr. Pankaj Chaturvedi

Oration 2: Institution building is career building" Dr. Rangi Prasad) by Dr Harit Chaturvedi

AWARDS

Abstract Competition

- 1st Prize- Dr. Afshan Afreen (Paras HMRI, Patna)
- 2nd Prize Dr. Anisha Singh (MCS, Patna)
- 3rd Prize-Dr. Avneet. Kaur (Paras HMRI, Patna)

Quiz Competition

- 1st Prize- Dr. Aman Kumar (IGIMS, Patna)
- 2 2nd Prize -Dr.Omal Shereef (MCS, Patna)



7th Annual Conference AROICON BIHAR CHAPTER 2025

KEYNOTE LECTURE

Keynote 1: Newer development in art of Radiotherapy in Lung Cancer in all stages by Dr. Balu Krishna Sasidharan Keynote 2:Epidemiology of gall bladder cancer in India and an update on Radiotherapy in Locally advanced Gall bladder carcinoma- A comprehensive review by Dr. Reena Engineer

Keynote 3: An overview on Re-irradiation in Head and Neck Cancers: What has been achieved so far? by Dr. Munish Gairola Keynote 4:A comprehensive and interdisciplinary overview on Nasopharyngeal CarcinomaPresent and future prospect by Dr.Sarbani Ghosh Laskar

Keynote 5: Increasing the value of Radiotherapy in Breast Cancer
Newer Innovations by Dr. Jyotirup Goswami
Keynote 6: The Evolving Landscape in Endometrial Cancers - From
staging to therapy by Dr Swaroopa Mitra

Keynote 7: Recent advances in anti-angiogenic therapy in the treatment of glioma and in combination with Radiotherapy by Dr.Rajesh Balakrishnan

Keynote 8:Radiotherapy advances in Glioblastoma - The Present and Future by Dr Indu Bansal





11th AROI -ESTRO Teaching Course

Pritanjali Singh
VICE PRESIDENT
AROI (Bihar Chapter)
Professor & Head
RADIATION ONCOLOGY
AIIMS, PATNA








nepartment of Radiation Oncology, AIIMS-Patna conducted a 11th AROI-ESTRO teaching course at AIIMS- Auditorium, Patna from 05th to 08th December 2024. The theme of the course is "Closing the gap with advancing technology". The teaching course is organized under the patronage of Dr. Saurabh Varshney, Executive Director, AIIMS-Dr. Anup Kumar, Medical Superintendent, AIIMS-Patna is chief guest on the Occasion. Programme is conducted under the supervision of Dr. Pritanjali Singh, Prof. & Head, Dept. of Radiation Oncology. Dignitaries. Dr. Manoj Gupta [AIIMS-Rishikesh], Dr. B.Sanyal [MCS,Patna], Dr. J.K.Singh [SS Hospital & Research centre, Patna], Dr. Rajeev Ranjan [Medanta Hospital, Patna] & Dr. P.N.Pandit grace the Occasion.

International Speakers participated in the workshop are Dr. Andrew Hope ,Radiation Oncologist, Princes Margrete Hospital Toronto, Dr. Ben Heijmen ,Medical Physicist & Prof. Radiation Oncology at Eramus MC Cancer Institute, GD Rotterdam & Dr. Mairead Daly [Radiographer, Cancer research UK].

The AROI Course Director Dr. Indranil Mallick, Sr. Consultant, Radiation Oncologist, TMC, Kolakata & ESTRO Course Director, Dr. Ben Heijmen, Medical Physicist Eramus MC Cancer Institute,GD Rotterdam guide the teaching course along with the National Faculties.



In last session Dr. Jyotirup Goswami give a talk on clinical trial design to assess new technology. Dr. T. Ganesh explained about flash therapy. Dr. Pritanjali singh, Dr. Indranil Mallick give take home message.

More than 100 Radiation Oncologist and Radiation Physicist are participating in the course to enhance their knowledge and advance in Radiation Oncology.



GLOBAL FIRST: INDIAN SCIENTISTS MAP CERVICAL CANCER AT MOLECULAR LEVEL, OPEN DOORS TO PRECISION TREATMENT

Dr Richa Chauhan Editor-in-chief (AROI Bihar Chapter) Sr. Consultant, Radiation Oncology MCS ,Patna

In a global first, Indian scientists and doctors have carried out a detailed study of cervical cancer, explaining why some patients do not respond to regular treatment and pointing to new, more effective options.

The landmark work, based on patient samples from Bihar, is the first in the world to combine a full genetic study with an analysis of proteins linked to cervical cancer. Experts say the findings could help develop treatments that are tailored to individual patients.

The study was conceptualised by Dr. Richa Chauhan, a senior Oncologist from Mahavir Cancer Sansthan, Patna. The research work was carried out by PhD students Janani Sambath and Irene A George under the mentorship of Dr. Prashant Kumar and clinical support from Dr. Chauhan.

Published in international journals Molecular Oncology and Molecular Omics, the study found two major changes in patients who did not respond to treatment—extra copies of a gene called EGFR, which pushes cancer cells to grow faster, and loss of another gene, STK11, which normally helps control cell growth. Researchers said these changes can be targeted with existing medicines, opening the door to new therapies.

The team also studied how proteins behave in cancer cells. They found one protein, CSNK2A1, was overactive in patients whose tumors resisted treatment. In lab tests, blocking this protein with a drug called silmitasertib and combining it with low-dose chemotherapy showed strong promise in stopping cancer growth. Another protein, STX3, was consistently found at high levels in resistant tumors. This protein is now patented in India as a marker that could help identify patients less likely to respond to regular therapy.

The study has already been recognised on the global stage. Dr. Kumar presented the findings at the ESMO Asia Congress 2024 in Singapore, where the team won the Best Poster Award among hundreds of international researchers.

"Cervical cancer is the second most common cancer among Indian women, making up nearly 10 per cent of all female cancers," Dr. Kumar said. "Even with vaccination drives, late detection remains common in states like Bihar. Our research, built entirely on Indian samples, is aimed at bringing real solutions for patients."

The team now plans to develop tests that can help doctors choose the best treatment in advance, and to move the new drug combinations into clinical trials.

REFERENCE

Sambath, J., George, I., Manda, S., Ariyannur, P., Dhawale, E., Kommu, R., Datar, R., Patil, D., Trivedi, V., Singh, M., Prabhash, K., Limaye, S., Chauhan, R., Kumar, P*., Integrated genomic and proteomic profiling reveals insights into chemoradiation resistance in cervical cancer. (2025) Molecular Oncology. (In-press)

George,I.A, Sambath, J., Dhawale. R.E., Singh, M., Trivedi, V., Venkataramanan.V., Chauhan.R., Kumar.P*., (2024) Phosphoproteomics guides low dose drug combination of cisplatin and silmitasertib against concurrent chemoradiation resistant cervical cancer. Molecular Omics (*Corresponding author)





I. A Promise for a Long-Waiting Region

For decades, North Bihar lived with a quiet sorrow—cancer care was always far away. Families travelled from Muzaffarpur to Mumbai, Sitamarhi to Varanasi, often reaching care too late or at unbearable cost. The burden of distance became a second disease.

The creation of Homi Bhabha Cancer Hospital & Research Centre (HBCHRC) was therefore not just an institutional milestone; it was a long-overdue act of justice.

In 2018, the Department of Atomic Energy (DAE) sanctioned the ninth unit of Tata Memorial Centre. The Government of Bihar provided 45 acres inside the SKMCH campus, ensuring the centre would rise within an existing healthcare ecosystem. A project of more than ₹570 crore was built jointly by ₹198 crore from DAE, ₹212 crore from the Bihar Government, and ₹160+crore from CSR partners whose generosity strengthened the foundation of HBCHRC.

II. Healing in a Temporary Home

As the main campus rose, cancer did not pause. HBCHRC began treating patients in 2021 from a prefabricated modular facility—humble in form, but transformative in impact. With generous support from SKMCH, which shared its OTs, ICUs, and blood bank, care began immediately.

In these formative years:

- 21,000+ patients were seen
- 60,000+ chemotherapy cycles were delivered
- · 3,000+ surgeries were completed
- 1.2 million diagnostics guided treatment
- 400+ children finished cancer therapy

A dharamshala sheltered families arriving from far-off districts; mobility support and buggies eased movement for frail patients; medical social workers bridged financial gaps; and Palliative Care became a quiet pillar—visiting homes, offering solace, and restoring dignity.

The modular phase proved that healing does not wait for grandeur—it begins wherever compassion lives.



HBCHRC Muzaffarpur: Where a Promise Became a Place of Healing

A Chronicle of Vision, Compassion, and the Quiet Triumph of Science

III. Leadership: A Symphony of Shared Purpose

- Purpose
 HBCHRC's journey from concept to reality was shaped by leaders who worked not in isolation but in harmony.
- At the helm of Tata Memorial Centre, Prof. Sudeep Gupta offered the vision and ethical compass that guided the project. His belief that world-class cancer care must reach underserved regions gave HBCHRC both direction and soul.
- Equally integral was the seamless partnership of Prof. Pankaj Chaturvedi, Director ACTREC, and Prof. Satyajit Pradhan, Director MPMMCC & HBCH. From the earliest meetings to the final days of commissioning, they functioned as a unified team—bringing academic strength, clinical insight, and operational discipline. Their joint stewardship is woven into every functioning department of HBCHRC.
- During commissioning, Prof. Kumar Prabhash assumed leadership of HBCHRC Muzaffarpur. His steady guidance transformed the newly built structure into a cohesive, patient-centred institution. Today, he leads HBCHRC's growth with clarity and purpose.
- Supporting the entire journey with tireless dedication is Dr. Ravikant Singh, Officer-in-Charge, whose hands-on coordination turned plans into functioning reality.
- Together, they shaped not just a building, but a sanctuary.

V. A Campus that Finally Felt Like Home

- by mid-2025, the fully constructed 150bed cancer centre stood ready—housing six operation theatres, ICU and HDU, histopathology and NGS labs, physiotherapy, preventive oncology, palliative suites, and an expansive daycare chemotherapy wing.
- On 22 August 2025, HBCHRC
 Muzaffarpur was inaugurated by Hon'ble
 Prime Minister Shri Narendra Modi,
 marking a moment when a regional
 dream touched national attention.
- Today, patient care is strengthened by:
- A dharamshala for families
- Campus transport and mobility assistance
- Medical social workers bridging financial access
- State Health Society (SHS) supporting screening and district chemotherapy
- A humane Palliative Care programme
 HBCHRC has become a place where science and compassion walk together.

VI. Radiotherapy: The Light Within the Samprada Singh Memorial Radiotherapy Centre

The radiotherapy facility bears a name of deep significance—

The Samprada Singh Memorial Radiotherapy Centre,

honouring the visionary philanthropist whose legacy has uplifted Indian healthcare.

The department's journey began on 10 December 2024 when the Halcyon E delivered its first beam. On 16 June 2025, the TrueBeam SVC extended this milestone with metropolitan-grade precision. Today, a second TrueBeam SVC, fully commissioned, ensures timely care for all.

The arrival of the SagiNova HDR Co-60 brachytherapy system transformed cervical cancer treatment—granting women access to curative therapy close to home.

Supported by the Somatom go.Sim CT simulator and a fully operational mould room, the department now treats nearly 150 patients each day, blending precision with compassion.

CSR partners shaped this department's heart:

- Indian Oil Corporation Ltd. enabled the Halcvon E
- Bharat Petroleum Corporation Ltd. strengthened brachytherapy
- Alkem Laboratories, honouring Shri Samprada Singh, built core radiotherapy infrastructure

Their generosity shines in every beam that heals.

VII. A Circle of Care

- The State Health Society (SHS), Bihar, expanded community screening and district oncology services.
- The Palliative Care Team brings tenderness where cure is not possible.
- And the early, steadfast support of SKMCH remains a foundational blessing.

VIII. When a Promise Becomes Home

 HBCHRC Muzaffarpur stands today as a symbol of what vision, unity, and compassion can create. It began as a need. It grew into a promise. And today, it is a home for healing.

Gautam K Sharan, Medical Officer 'G' & Consultant, Radiation Oncology Kumar Prabhash, Director Ravikant Singh, Officer-in-Charge

PRIMARY MALIGNANT MELANOMA OF CNS

MELANIN IN THE MIND: UNMASKING PRIMARY ONS MALIGNANT MELANOMA


INTRODUCTION

Primary melanocytic neoplasms of the central nervous system (CNS) are rare and account for 1% of all melanomas. This study used the Surveillance, Epidemiology, and End Results (SEER) database to evaluate the epidemiology of primary CNS melanoma and further characterize their treatment. Given its rarity, limited data exist to guide management. Treatment typically involves surgical resection followed by adjuvant radiotherapy and, in select cases, immunotherapy.


CASE SUMMARY


A 48-year-old female presented with a 5-month history of dull, progressive headache, nausea, vertigo, blurred vision, seizures with episodes of LOC, and confusion. Clinical examination revealed disorientation, right-sided facial weakness, limb weakness, and papilledema.Brain MRI showed a 6 \times 4 \times 7.8 cm Left frontal subcortical area lesion that was hyperintense on T1 and hypointense on T2, suggesting a melanin-rich or hemorrhagic tumor.

Whole-body PET-CT ruled out any extracranial malignancy. The patient underwent a craniotomy with near-total excision of a pigmented, demarcated vascular, and welltumor. Histopathological analysis revealed pigmented spindle and epithelioid cells with pleomorphic nuclei and high mitotic activity. Immunohistochemistry was positive for HMB-45, S100, and Melan-A, with a Ki-67 index of 30%, but negative for cytokeratin confirming the diagnosis of malignant melanoma. Solid-cystic nature of the lesion, the cystic component showing hypointense signal on T2 and hyperintense signal on T1 with fluid-fluid level with mass effect causing midline shift of lateral ventricle. The patient subsequently received radiotherapy (RT) to 30 Gy in 10 fractions as part of adjuvant management.



The tumor cells show strong cytoplasmic expression of HMB-45 and strong nuclear expression of SOX10






Pleomorphic cells with melanin pigmentation on high power field examination. Cytoplasmic positive Melan A





She experienced symptomatic post-radiotherapy, with reduction in vertigo, headache severity, and stabilization of neurological deficits. At 3-month follow-up, the patient demonstrated clinical improvement with no new neurological deficits. MRI brain showed postoperative

changes disease without evidence of progression. Ongoing surveillance multidisciplinary imaging and evaluation were planned due to the high risk of recurrence associated with primary CNS melanoma.




DISCUSSION

Primary CNS MM is extremely rare, arising from leptomeningeal MCs, with most CNS MMs being metastatic. Diagnosis needs exclusion of extracranial origin via PET-CT and systemic evaluation. Common symptoms include seizures, FNDs, AMS, and raised ICP. MRI typically shows T1 hyperintense and T2 hypointense lesions due to melanin. Histology and IHC (HMB45, S100, Melan-A) confirm diagnosis. Tx includes surgery, RT, and emerging IT. Prognosis is poor, with median survival of 12–24 months and limited data.

CONCLUSION

Primary CNS malignant melanoma is a rare, aggressive tumor requiring accurate diagnosis and multidisciplinary treatment, with limited survival benefits from current therapies.



ACADEMIC ACHIEVEMENTS - DEPARTMENT OF RADIATION ONCOLOGY



DR. AEEZEEN FARRUKH

3RD YEAR DNB, (RADIATION ONCOLOGY)

MCS,


PATNA



We are pleased to share the recent academic accomplishments of our residents have represented our institution with excellence at national oncology platforms.

Dr. Aeezeen Aaquib Farrukh and Dr. Omal Shereef were recognised as "Performers of the Week" in the OSCE Educative Oncology Project for their consistent participation, clinical proficiency, and dedication to continuous learning.

Adding to these achievements, Dr. Omal Shereef also secured the Winner's position in the 51st AROI SUN Quiz, reflecting her outstanding knowledge and competitive excellence in radiation oncology.



DR. OMAL SHEREEF

3RD YEAR DNB, (RADIATION ONCOLOGY)

MCS,
PATNA



We also congratulate Dr. Banti, 3rd year Resident, IGIMS, Patna was selected as a runner-up in the ICRO IMPACT Panel Discussion at AROICON 2024, Mangalore, showcasing his expertise and contributing meaningfully to academic dialogue at a prestigious national forum.



DR. BANTI KUMAR

3RD YEAR MD, (RADIATION ONCOLOGY)
IGIMS,
PATNA

These achievements highlight the dedication, academic growth, and professional excellence of young radiation oncology professionals in the region. We extend our best wishes to all for continued success in their academic and clinical endeavors.

ACADEMIC ACHIEVEMENTS - DEPARTMENT OF RADIATION ONCOLOGY

The Department of Radiation Oncology proudly acknowledges the successful completion of training by several Junior Residents across premier institutions.

From AIIMS, Patna- Dr. Janvi Kodela (Batch 2022–2025) has successfully passed her junior residency.

From IGIMS, Patna, the following MD residents completed their tenure:


Batch 2021–2024:Dr. Monirul Mondal, Dr. Supriya Verma, Dr. Madhuvanti Anand, Dr. Raina Rana

Batch 2022–2025:Dr. Priti, Dr. Kaniz Fatima, Dr. Debopam Purkasthya, Dr. Banti Kumarn.

From MCS, Patna, the following DNB residents completed their tenure:

Batch 2021–2024: Dr. Tanmoy, Dr. Al Safa, Dr. Maria Joseph, and Dr. Rajavel M

Batch 2022-2025: Dr. Anisha Singh, Dr. Aezeen, and Dr. Tuba Ansari



Upcoming Event







1st Announcement

13th - 14th

Venue: Auditorium
IGIMS,Patna- 14

December 2025



10th Annual Conference of East Oncology Group & 29th Foundation Day, State Cancer Institute, IGIMS


THEME: FAITH, HOPE & CURE





Oranizing Secretary
Dr (Prof) Rajesh Kumar Singh
Chief SCI, IGIMS, Patna- 14
Mob.: +91 99390 88899

Email: oncoconeog@gmail.com profsinghrajesh@gmail.com www.eastoncologygroup.com



Dear Members, Let's connect
Do share your write-ups, ideas,
suggestions, achievements and
photograph of events by sending
email at editor.aroibihar@gmail.com